标题：Research Grade Cetuximab 西妥昔单抗,AntibodySystem Laboratories
链接：https://www.antibodysystem.com/product/10059.html
名称：Research Grade Cetuximab西妥昔单抗
别名：Cetuximab西妥昔单抗，Fab C225, IMC-225, cetuximab-IR700
CAS: 205923-56-4
货号：DHB86902
适用物种：Human
寄主物种：Chimeric
形式：Liquid
纯度：>95%
克隆性：Monoclonal
同种型：IgG1-kappa
应用：Research Grade Biosimilar
UniProt：P00533
靶点：HER1, Receptor tyrosine-protein kinase erbB-1, Proto-oncogene c-ErbB-1, Epidermal growth factor receptor, EGFR, ERBB1, ERBB
用途范围：仅用于科研
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：products@biolabreagent.com
选购商城：https://www.antibodysystem.com
微信公众平台：佰乐博生物Biolab Reagents
参考文献：
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. PMID: 36546659
Cetuximab for treating non-small cell lung cancer. PMID: 29534625
Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. PMID: 34775496
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. PMID: 30449625
Cetuximab-induced bullous pemphigoid. PMID: 36939515
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. PMID: 36522816
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. PMID: 36117191
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. PMID: 30199311
Cetuximab every 2 weeks versus standard weekly dosing administration schedule. PMID: 37850363
Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance. PMID: 34245856
Cetuximab and the Head and Neck Squamous Cell Cancer. PMID: 29332581
Radiotherapy plus cetuximab or cisplatin in head and neck squamous cell carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. PMID: 35986743
Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS(G12D) Inhibitor, in Colorectal Cancer Treatment. PMID: 37772552
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. PMID: 37721754
Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event. PMID: 27378078
Cetuximab monotherapy for relapsing high-grade mucoepidermoid carcinoma: A case report and review of the literature. PMID: 32518035
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. PMID: 33989949
Cetuximab: Its role in patients unfit for cisplatin. PMID: 34864298
3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis. PMID: 37558749
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. PMID: 37557179
Cost-effectiveness of cetuximab for colorectal cancer. PMID: 27750444
Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction. PMID: 36899869
Cetuximab associated dermal filler reaction. PMID: 31451454
A Critical Review of Properties and Analytical/Bioanalytical Methods for Characterization of Cetuximab. PMID: 30869993
Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials. PMID: 25794489
Near-infrared photoimmunotherapy in the models of hepatocellular carcinomas using cetuximab-IR700. PMID: 37817415
Cetuximab enhances radiosensitivity of esophageal squamous cell carcinoma cells by G2/M cycle arrest and DNA repair delay through inhibiting p-EGFR and p-ERK. PMID: 37337933
Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis. PMID: 36253001
Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. PMID: 27340349
Cetuximab-conjugated PLGA nanoparticles as a prospective targeting therapeutics for non-small cell lung cancer. PMID: 37010248
Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer. PMID: 36932871
Cetuximab and Radiotherapy in Laryngeal Preservation. PMID: 28006053
Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms? PMID: 32275949
Trichomegaly Induced by Cetuximab: Case Series and Review the Literature. PMID: 26079631
Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer. PMID: 31678385
Pinnae and facial hypertrichosis induced by cetuximab. PMID: 35821579
Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis. PMID: 31578019
The role of IgE specific for galactose-alpha-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis. PMID: 33288791
Potentially Resectable mCRC-treated with Cetuximab Combined with Chemotherapy. PMID: 33222742
Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients. PMID: 37442917
